WCLC 2026
Join us in Seoul in 2026 for an exceptional program featuring world-renowned speakers, emerging investigators, and leaders across every discipline of thoracic oncology. Together, we will exchange ideas, build collaborations, and celebrate the progress our community continues to make toward improving patient outcomes worldwide. We warmly invite physicians, nurses, researchers, scientists, patients, survivors, and advocates to be part of this inspiring event. Your participation strengthens our shared mission and helps drive meaningful change in lung cancer prevention, diagnosis, and care. We look forward to welcoming you to Seoul in September 2026 for an engaging, educational, and unforgettable experience.
WCLC 2026: Subcutaneous tarlatamab shows favourable safety profile and antitumour activity in extensive-stage small cell lung cancer
WCLC 2026: Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC
WCLC 2026: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
WCLC 2026: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer
WCLC 2026: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
WCLC 2026: MRI surveillance reduces cognitive decline compared with prophylactic cranial irradiation in SCLC
WCLC 2026: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
WCLC 2026: Mobile CT lung cancer screening expands access for underserved populations in Brazil
WCLC 2026: Brain MRI surveillance without prophylactic cranial irradiation improves cognitive outcomes in small cell lung cancer
WCLC 2026: Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
WCLC 2026: Pumitamig plus elfetabart drozuntecan shows encouraging early activity in small cell lung cancer
WCLC 2026: Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC
WCLC 2026: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC
WCLC 2026: Brain MRI surveillance without prophylactic cranial irradiation improves cognitive outcomes in small cell lung cancer
WCLC 2026: Investigator presents final PAPILLON trial results showing long-term survival in a subset of lung cancer
WCLC 2026: Mobile CT lung cancer screening expands access for underserved populations in Brazil
WCLC 2026: Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
WCLC 2026: Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
WCLC 2026: Study identifies distinct outcomes and genomic features in NSCLC with class II and III BRAF alterations
WCLC 2026: Analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-positive advanced NSCLC
WCLC 2026: Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
WCLC 2026: Trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer
WCLC 2026: Trial supports brain MRI surveillance alone as standard of care for small-cell lung cancer
WCLC 2026: Study shows first-line amivantamab plus chemotherapy achieves longest overall survival reported in advanced NSCLC with EGFR exon 20 insertions
WCLC 2026: Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC
WCLC 2026: Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC
WCLC 2026: Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC
Tarlatamab's role in SCLC
WCLC 2026: Lung cancer research highlights
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC
Using artificial intelligence to improve lung cancer screening and risk prediction
Subcutaneous tarlatamab shows encouraging efficacy in previously treated extensive-stage SCLC
Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma
Functional dependence predicts poorer survival in adults aged 80 and over with NSCLC
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC
Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Challenges in doing clinical research in the LATAM region
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC
Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC